Recent research about lung cancer showed that low-dose carboplatin, the cornerstone of platinum drugs in lung cancer, changes the ‘cold’ tumor with less anti-tumor cell infiltration into a ‘hot’ tumor with higher infiltration via the signaling center STING and increases PD-L1 expression (200, 201). This evidence concerns the gene STING1 and lung cancer.